Novo Nordisk to Launch Ozempic in India This Month Amid Growing Weight-Loss Market. Novo Nordisk is set to launch its blockbuster diabetes drug Ozempic in India this month, marking a significant step in expanding its presence in the country. India, with the second-largest population of type 2 diabetes patients globally, represents a key market for Novo Nordisk, especially as obesity rates rise. Ozempic, a weekly injectable approved for type 2 diabetes, has become a global bestseller and is also widely used off-label for weight loss. Novo Nordisk aims to introduce Ozempic ahead of the anticipated arrival of generics, which could offer more affordable alternatives. The company is working to price Ozempic competitively for the price-sensitive Indian market, according to Vikrant Shrotriya, Managing Director of Novo Nordisk India. The launch of Ozempic will complete Novo’s semaglutide portfolio in India, offering treatments for both diabetes and obesity. As Wegovy faces stiff competition from Eli Lilly’s Mounjaro, Novo is poised to leverage its strong brand reputation in India’s diabetes market. Eli Lilly’s Mounjaro, approved for both diabetes and weight loss, was India’s top-selling drug by value in October, outpacing Novo’s Wegovy. Novo’s price cuts for Wegovy in India, ahead of the expiration of its semaglutide patent in 2026, reflect the growing competition from generics. Indian generic manufacturers like Sun Pharma and Cipla are developing their own versions of semaglutide to capitalize on the weight-loss market.